Cinitapride

Targets (3)Biointeractions (3)

Identification

Name
Cinitapride
Accession Number
DB08810
Type
Small Molecule
Groups
Approved, Investigational
Description

Cinitapride is a gastroprokinetic agent and antiulcer agent of the benzamide class which is marketed in Spain and Mexico. It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors.

Structure
Thumb
3D
Similar Structures
Synonyms
  • Paxapride
International/Other Brands
Blaston / Cinmove / Cintapro / Paxapride / Pemix
Categories
UNII
R8I97I2L24
CAS number
66564-14-5
Weight
Average: 402.4873
Monoisotopic: 402.226705468
Chemical Formula
C21H30N4O4
InChI Key
ZDLBNXXKDMLZMF-UHFFFAOYSA-N
InChI
InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)
IUPAC Name
4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
SMILES
CCOC1=CC(N)=C(C=C1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O

Pharmacology

Indication

For the treatment of gastrointestinal disorders associated with motility disturbances such as gastroesophageal reflux disease, non-ulcer dyspepsia and delayed gastric emptying.

Pharmacodynamics
Not Available
Mechanism of action

Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.

TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
agonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 4
agonist
Human
Absorption

The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.

Clearance
Not Available
Toxicity

The symptoms of overdose include drowsiness, confusion and extrapyramidal effects.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Cinitapride can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Cinitapride.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cinitapride.
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Cinitapride.
AmitriptylineThe risk or severity of serotonin syndrome can be increased when Amitriptyline is combined with Cinitapride.
AmphetamineThe risk or severity of serotonin syndrome can be increased when Cinitapride is combined with Amphetamine.
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Cinitapride.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cinitapride.
BenmoxinThe metabolism of Cinitapride can be decreased when combined with Benmoxin.
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Cinitapride is combined with Benzphetamine.
Food Interactions
Not Available

References

General References
  1. Alarcon-de-la-Lastra Romero C, Lopez A, Martin MJ, la Casa C, Motilva V: Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202. [PubMed:9211565]
External Links
Human Metabolome Database
HMDB0015698
KEGG Drug
D07700
PubChem Compound
68867
PubChem Substance
175427098
ChemSpider
62099
ChEBI
135642
ChEMBL
CHEMBL2104523
PharmGKB
PA165958427
Wikipedia
Cinitapride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentIndigestion1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0141 mg/mLALOGPS
logP3.7ALOGPS
logP2.79ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area113.41 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity115.58 m3·mol-1ChemAxon
Polarizability44.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9916
Blood Brain Barrier+0.9314
Caco-2 permeable-0.5973
P-glycoprotein substrateSubstrate0.8692
P-glycoprotein inhibitor IInhibitor0.5895
P-glycoprotein inhibitor IINon-inhibitor0.8347
Renal organic cation transporterNon-inhibitor0.7496
CYP450 2C9 substrateNon-substrate0.8928
CYP450 2D6 substrateNon-substrate0.8126
CYP450 3A4 substrateSubstrate0.5721
CYP450 1A2 substrateNon-inhibitor0.6663
CYP450 2C9 inhibitorNon-inhibitor0.7521
CYP450 2D6 inhibitorNon-inhibitor0.7862
CYP450 2C19 inhibitorInhibitor0.5746
CYP450 3A4 inhibitorNon-inhibitor0.5286
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5396
Ames testAMES toxic0.6766
CarcinogenicityNon-carcinogens0.7628
BiodegradationNot ready biodegradable0.8614
Rat acute toxicity2.6773 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5217
hERG inhibition (predictor II)Inhibitor0.6969
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrophenyl ethers. These are aromatic compounds containing a nitrobenzene moiety that carries an ether group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Nitrobenzenes
Direct Parent
Nitrophenyl ethers
Alternative Parents
Aminobenzamides / Aminophenyl ethers / Benzamides / Phenoxy compounds / Aniline and substituted anilines / Nitroaromatic compounds / Benzoyl derivatives / Alkyl aryl ethers / Piperidines / Trialkylamines
show 10 more
Substituents
Nitrophenyl ether / Aminobenzamide / Aminobenzoic acid or derivatives / Aminophenyl ether / Benzamide / Benzoic acid or derivatives / Phenoxy compound / Nitroaromatic compound / Benzoyl / Phenol ether
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details1. 5-hydroxytryptamine receptor 1A
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Alarcon-de-la-Lastra Romero C, Lopez A, Martin MJ, la Casa C, Motilva V: Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202. [PubMed:9211565]
  2. Alarcon de la Lastra C, La Casa C, Martin MJ, Motilva V: Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6. [PubMed:9562338]
Details2. 5-hydroxytryptamine receptor 2A
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Alarcon-de-la-Lastra Romero C, Lopez A, Martin MJ, la Casa C, Motilva V: Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202. [PubMed:9211565]
  2. Alarcon de la Lastra C, La Casa C, Martin MJ, Motilva V: Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6. [PubMed:9562338]
Details3. 5-hydroxytryptamine receptor 4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. Alarcon-de-la-Lastra Romero C, Lopez A, Martin MJ, la Casa C, Motilva V: Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202. [PubMed:9211565]
  2. Alarcon de la Lastra C, La Casa C, Martin MJ, Motilva V: Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6. [PubMed:9562338]

Drug created on January 19, 2011 16:47 / Updated on August 02, 2018 06:10